Get informed when a big investor buys or sells
+ FollowOvervalued by 146.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $5.47 Million |
|---|---|
| Enterprise Value | $8.90 Million |
| Earnings per Share | $-0.03 |
| Beta | 0.61 |
| Outstanding Shares | 204,994,910 |
| P/E Ratio | -2.02 |
|---|---|
| PEG | -2.04 |
| Price to Sales | - |
| Price to Book Ratio | -0.03 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.06 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.4 |
| Debt to Equity | -0.62 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for t...